Najat Khan
Known title: CEO and PresidentCIK: 0002020969
Associated companies
Transaction History
| RXRX | ▼ Sell | Open Market | 22,408 | $79K | 9/8/2026 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 80,498 | $254K | 8/17/2026 | View on chart |
| RXRX | ▼ Sell | Open Market | 23,588 | $84K | 6/5/2026 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 62,701 | $191K | 5/15/2026 | View on chart |
| RXRX | ▼ Sell | Open Market | 28,298 | $95K | 3/9/2026 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 14,280 | $50K | 2/17/2026 | View on chart |
| RXRX | ▲ Buy | Grant | 1,673,546 | $0 | 2/6/2026 | View on chart |
| RXRX | ▲ Buy | Grant | 30,346 | $0 | 2/6/2026 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 10,364 | $41K | 2/6/2026 | View on chart |
| RXRX | ▼ Sell | Open Market | 124,403 | $549K | 12/22/2025 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 17,584 | $73K | 11/17/2025 | View on chart |
| RXRX | ▲ Buy | Grant | 84,925 | $0 | 11/5/2025 | View on chart |
| RXRX | ▼ Sell | Open Market | 36,599 | $202K | 8/18/2025 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 3,789 | $21K | 8/15/2025 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 3,796 | $16K | 5/15/2025 | View on chart |
| RXRX | ▲ Buy | Grant | 210,113 | $0 | 2/3/2025 | View on chart |
| RXRX | ▲ Buy | Grant | 8,049 | $0 | 2/3/2025 | View on chart |
| RXRX | ▼ Sell | Tax Withholding | 2,753 | $20K | 2/3/2025 | View on chart |
| RXRX | ▲ Buy | Grant | 496,972 | $0 | 8/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings
Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings. Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.